Adam Khatab M, Abdelrahim Elfatih Yousif, Doush Wael Mohialddin, Abdelaziz Muataz S
Department of Gastroenterological Surgery Ibn Sina Specialized Hospital Khartoum Sudan.
Department of Surgery, Faculty of Medicine and Health Sciences Omdurman Islamic University Khartoum Sudan.
JGH Open. 2023 Apr 25;7(5):365-371. doi: 10.1002/jgh3.12906. eCollection 2023 May.
Gallbladder cancer (GBC) is a rare and highly aggressive malignancy characterized by late presentation of nonspecific symptoms, poor curability, and high mortality. The gold standard for effective treatment depends on early detection and surgical excision. Hence, the aim of this study was to determine the patterns of clinical presentation and management modalities to reach excellent practice.
A retrospective study was conducted during the period from May 2021 to April 2022 at Ibn Sina specialized hospital, Khartoum, Sudan, on 50 patients with GBC who underwent a preoperative clinical and radiological evaluation to enable the use of appropriate surgical and oncological approaches.
GBC was more prevalent in females in this series where all had GBC (68%), in the ratio 2:1. Distribution of patients according to age ranged between 61 and 75 years, representing 44% of patients. Abdominal pain, nausea, and vomiting were present in 40% of patients. Fifty-six percent of patients resided in urban areas. Transabdominal ultrasound (TUS) with CT scan diagnosed GBC in 54% of patients. GBC was metastatic (stage IV) in 52% of patients. Based on preoperative decision by a multidisciplinary team (MDT), 62% of patients had palliative nonsurgical oncological treatment. Histopathological analysis of the resected GBC showed adenocarcinoma in 74% of cases. The inoperable patients (42%) were treated palliativelly with endoscopic retrograde cholangiopancreatography/systemic chemotherapy. Finally, the overall mortality rate was 56%.
Accurate early clinical diagnosis and advanced radiological modalities with curative surgical approaches including clear surgical resection margins and systemic oncological therapies will potentially help in improving GBC survival outcomes.
胆囊癌(GBC)是一种罕见且侵袭性很强的恶性肿瘤,其特点是出现非特异性症状较晚、治愈率低且死亡率高。有效治疗的金标准取决于早期发现和手术切除。因此,本研究的目的是确定临床表现模式和管理方式,以实现最佳实践。
2021年5月至2022年4月期间,在苏丹喀土穆的伊本·西那专科医院对50例胆囊癌患者进行了一项回顾性研究,这些患者接受了术前临床和影像学评估,以便采用适当的手术和肿瘤学方法。
在本系列中,胆囊癌在女性中更为普遍,所有患者均患有胆囊癌(68%),男女比例为2:1。患者年龄分布在61至75岁之间,占患者总数的44%。40%的患者出现腹痛、恶心和呕吐。56%的患者居住在城市地区。经腹超声(TUS)联合CT扫描诊断出54%的患者患有胆囊癌。52%的患者胆囊癌已发生转移(IV期)。根据多学科团队(MDT)的术前决定,62%的患者接受了姑息性非手术肿瘤治疗。对切除的胆囊癌进行组织病理学分析,74%的病例显示为腺癌。无法手术的患者(42%)接受了内镜逆行胰胆管造影术/全身化疗的姑息治疗。最后,总死亡率为56%。
准确的早期临床诊断、先进的影像学检查方法以及包括明确手术切缘的根治性手术方法和全身肿瘤治疗,可能有助于改善胆囊癌的生存结果。